Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP) (STARSHIP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00653965 |
Recruitment Status :
Completed
First Posted : April 7, 2008
Last Update Posted : March 16, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypercholesterolemia Dyslipidaemia | Drug: Rosuvastatin Drug: Atorvastatin | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 3000 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A 6-Week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolaemia in Hispanic Subjects. |
Study Start Date : | May 2003 |
Actual Study Completion Date : | February 2005 |

Arm | Intervention/treatment |
---|---|
Experimental: 1
Rosuvastatin
|
Drug: Rosuvastatin
Other Name: Crestor |
Active Comparator: 2
Atorvastatin
|
Drug: Atorvastatin
Other Name: Lipitor |
- Low density lipoproteins cholesterol levels [ Time Frame: 6 weeks ]
- Other blood lipid level changes [ Time Frame: 6 weeks ]
- Safety: adverse events & abnormal laboratory markers [ Time Frame: 6 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Fasting low density lipoprotein & triglyceride levels as defined by the protocol.
- Self described Hispanic race
- Subjects with coronary heart disease or at high risk of coronary heart disease.
Exclusion Criteria:
- The use of lipid lowering drugs or dietary supplements after Visit 1.
- Active arterial disease eg Unstable angina, or recent arterial surgery
- Blood lipid levels above the limits defined in the protocol.
- Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00653965
Principal Investigator: | Steve Haffner, MD | San Antonio, USA | |
Study Director: | Russell Esterline | AstraZeneca |
Responsible Party: | Elisabeth Björk, AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00653965 |
Other Study ID Numbers: |
4522US/0007 D3560L00027 |
First Posted: | April 7, 2008 Key Record Dates |
Last Update Posted: | March 16, 2009 |
Last Verified: | March 2009 |
Cholesterol low density lipoproteins dyslipidaemia Rosuvastatin |
Crestor Atorvastatin Lipitor Hispanic |
Hypercholesterolemia Dyslipidemias Hyperlipidemias Lipid Metabolism Disorders Metabolic Diseases Atorvastatin Rosuvastatin Calcium |
Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Enzyme Inhibitors |